Plasminogen activator inhibitor-1 (PAI-1), a rapid inhibitor of tissue-type plasminogen activator, has been shown to be an independent risk factor for recurrent myocardial infarction (MI) at a young age. To investigate whether genetic variation in the PAI-1 gene is affecting plasma PAI-1 levels, a sample of 145 patients with an MI before the age of 45 years was genotyped for two polymorphisms at the PAI-1 locus, together with a sample of 95 healthy individuals of a similar age. All individuals were measured for plasma PAI-1 levels as well as for other fibrinolytic and metabolic risk indicators. A HindlU restriction fragment length polymorphism (RFLP) was used in this study in conjunction with a previously unreported eight-allele dinucleotide repeat polymorphism at the PAI-1 locus. The dinucleotide repeat polymorphism and HindUl RFLP were in strong linkage disequilibrium. There was no difference in the frequency of alleles of either polymorphism between patient and control groups. However, the smaller dinucleotide repeat alleles were significantly associated (p=0.03) with higher plasma PAI-1 levels in the patient sample. This association was also apparent in the control sample but not at significant levels. Differences in regression coefficients for the effect of triglycerides on plasma PAI-1 levels suggest that triglyceride regulation of PAI-1 is genotype specific Our data suggest that genetic variation at this locus contributes to between-individual differences in the level of plasma PAI-1, which is important in fibrinolysis and the pathogenesis of MI. (Arteriosclerosis and Thrombosis 1991;ll: [183][184][185][186][187][188][189][190] 
T he conversion of plasminogen to proteohytically active plasmin by plasminogen activators is a crucial step in the fibrinolytic process. 1 Plasminogen activator inhibitor-1 (PAI-1) is a fast-acting inhibitor of tissue-type plasminogen activator (t-PA), the major proteolytic activator of plasminogen in vivo. 2 
"
3 PAI-1 is a glycoprotein with a molecular weight of 50,000 d and is a member of the serine protease inhibitor family, with an arginine residue at the reactive center.
2 -4 PAI-1 exists in two forms in plasma, with the active form existing as a complex bound to vitronectin. 5 -6 In the past few years, there have been numerous CToss-sectional studies of patients with angina pectoris or previous myocardial infarction (MI). These studies have consistently shown a decreased fibrinolytic activity in patients compared with controls, a decrease that is due mainly to elevated plasma levels of PAI-1. 7 - 11 Strong support for a cause-and-effect relation between PAI-1 elevation and risk of MI has been obtained from a longitudinal cohort study of 109 unselected men who had survived a first MI before the age of 45 years. This study indicated that a high plasma concentration of PAI-1 activity was associated with reinfarction, along with dyslipoproteinemia, poor left ventricular performance, and multiple-vessel coronary artery disease. 12 In addition, increased plasma PAI-1 activity has been suggested to have pathogenic importance in patients with deepvein thrombosis 13 and in diabetics. In this study, we used two polymorphisms at the PAI-1 locus to investigate the possibility that genetic variation at the PAI-1 locus contributes to altered plasma levels of PAI-1 and therefore to disease incidence.
Methods

Samples
The sample of 145 patients and 95 controls was recruited from Stockholm County, Sweden. All patients suffered a first MI before the age of 45 years, and the clinical procedures used to assess cardiovascular disease were those as described by Hamsten et al. 12 The control sample consisted of randomly selected, age-matched, healthy residents of Stockholm County. Of the 145 patients, 38 were excluded from the analysis due to familial hypercholesterolemia or diabetes mellitus, leaving 107 patients, 92 men and 15 women, who took part in a follow-up study based on serial coronary angiograms. Analysis was done with and without data from the 15 female patients. Linkage disequilibrium analysis on the two polymorphisms also included data from the other 38 individuals. All individuals in the study are unrelated and are of Swedish origin, except for 10 patients who had one or more parent and/or grandparent born in Finland.
Many hemostatic and metabolic variables were measured for each individual, 8 and a summary of several of these is shown in Table 1 . Serum lipoproteins were determined by a combination of preparative ultracentrifugation and precipitation of apolipoprotein (apo) B-containing lipoproteins, followed by lipid analyses in the major lipoprotein fractions. 19 Oral glucose tolerance was assessed after ingestion of glucose in a dose of 1.75 g/kg body wt. 20 Glucose was measured in whole blood by the glucose oxidase method, 21 and plasma insulin was measured by a double-antibody radioimmunoassay. 22 Plasma PAI-1 activity was determined by adding a certain amount of t-PA to diluted plasma and measuring residual t-PA activity.
2 - 23 The family used to study the inheritance of the dinucleotide repeat sequence was initially identified from the Rheumatology Clinic at Guy's Hospital for a study of joint hypermobility syndrome.
DNA Analysis
A 2.9-kilobase (kb) PAI-1 cDNA probe described previously 24 was used in hybridization analysis and was kindly provided by Tor Ny, University of Umea, Sweden. The Hindlll polymorphism was that first described by Klinger et al. 15 DNA was prepared from blood using standard techniques. 25 A P-labeled probe was generated using the method of Feinberg and Vogelstein, 26 and Amersham International cytidine-5'-[a-
32 P]triphosphate (aCTP), Amersham, Buckinghamshire, U.K. Standard Southern blotting was performed using Amersham Hybond N, and filters were washed to a final concentration of l x standard saline citrate and 0.1% sodium dodecyl sulfate after hybridization to a 32 P-labeled PAI-1 cDNA probe at 65°C. 25 The filters were then exposed to Amersham Hyperfilm for 24 hours at -70°C.
Dinucleotide Repeat Polymorphism
GenBank databases (GenBank, Los Alamos, N.M.) with DNAstar computer software were used in sequence analysis. 27 Amplification of the (C-A) n region in the PAI-1 gene was achieved with two 26-mer oligonucleotides synthesized on a Pharmacia Gene Assembler, Pharmacia, Uppsala, Sweden, by the Biochemistry Department, Charing Cross and Westminster Medical School ( Figure 1 ). Conditions for the polymerase chain reactions (PCRs) were standard 28 -29 using 1 /xg genomic DNA and 250 ng of each primer in a volume of 50 jtl. Each PCR reaction mixture contained 200 /imoles each of thymidine-5'-triphosphate, guanosine-5'-triphosphate, and aCTP, 100 Aimoles each oATP plus 100 ^moles [a-^S] aATP, 10 mM Tris HC1 (pH 8.3), 1.5 mM MgCl 2 , 50 mM KC1, 5fi\ dimethyl sulfoxide, and 1 unit PerkinElmer Taq polymerase. Samples were overlaid with paraffin oU and underwent one cycle of 3 minutes at 90°C, of 1 minute at 55°C, and of 1 minute at 72°C, and then 50 cycles of 1 minute at 90°C, of 1 minute at 55°C, and of 1 minute at 72°C. Half the resulting PCR species was mixed with 4 /il formamide running buffer after ethanol precipitation and was run on a denaturing polyacrylamide gel for approximately 4 hours. The gel was then dried and exposed to Amersham Hyperfilm /3-max for 2-3 days. Bacteriophage M13 mplO vector DNA was used as a template to produce a dideoxy sequencing ladder, which was used to size the PCR species. PAI (CA)n Repeat 
TCACTTGTCC CC 7S80
Statistical Analysis X 1 analysis was used to determine whether there was any significant difference in allele or genotype frequencies between control and patient samples. A stepwise regression of the PAI-1 value was performed separately in both patient and control samples after adjusting for age, body mass index (BMI), very low density lipoprotein triglycerides (VLDL-TG), and oral glucose tolerance test (OGTT). Analysis was performed with and without the 10 Finnish patients, and results were not significantly different. These adjusted PAI-1 values were then used in standard analysis of variance (ANOVA) and t test statistical tests to assess whether genotype had a statistically significant effect on plasma PAI-1 levels. Regression analysis was also performed separately in each genotype class of the HindlW RFLP to compare the regression slopes. One individual with an extremely high PAI-1 value was excluded from the final analysis on the basis that this value was extreme (defined as a value more than three interquartile ranges above the 75th percentile) and therefore having a disproportionately large effect on the statistical analysis of the data. An "average excess" calcu- Results The (C-A) n repeat polymorphism used in the study is shown in Figure 1 . In the previously reported HindlU RFLP, 1 ' the "2" allele represents the presence of an additional Hindlll site compared with the "1" allele. The (C-A) n repeat sequence within the PAI-1 gene identified from GenBank databases with DNAstar computer software was found to be a length polymorphism with eight alleles detected in the sample. Each allele differed from another by the number of -CA-dinucleotides in the repeat sequence, that is, by multiples of two base pairs. This concurs with the results of Weber and May, 27 who found similar polymorphisms at many other loci. Nomenclature of the dinucleotide repeat alleles was as suggested by Weber and May, the most frequent allele being designated "z" and the other alleles designated by their base-pair differences from z, that is, "z+2, z+4. ... ". As with other dinucleotide repeat polymorphisms, the PAI-1 polymorphism was found to be inherited in a mendelian fashion in an extended family (Figure 2 ). Individuals in this family had five different alleles, and the fragment sizes observed were constant over three generations (six informative meioses).
The patient and control samples were genotyped for both the Hindlll RFLP and the dinucleotide repeat polymorphism. As shown in Table 2 , these two polymorphisms are significantly correlated (p<0.001), suggesting that they are in strong linkage disequilibrium, the larger C-A repeat alleles being in disequilibrium with the Hindlll 2 allele. There was no significant difference between the frequency of any allele in the patient and control samples. Both polymorphisms were in Hardy-Weinberg equilibrium.
The characteristics of the patient and control samples are summarized in Table 1 . Significant differences between the two samples have been discussed previously, among them the reduced fibrinolytic activity in patients due to increased levels of plasma PAI-1. 8 Stepwise regression analysis of plasma PAI-1 levels against BMI, VLDL-TGs, and incremental insulin during the OGTT showed that in the patient sample, only VLDL-TGs and BMI had a significant independent effect on plasma PAI-1 levels, and these were included in the regression equation. In the control sample, BMI was not included in the regression equation, as it was found not to have a significant independent effect on PAI-1 levels. VLDL-TG levels explained 18.2% of the PAI-1 variation in patients and 40.0% of the variation in controls; BMI explained an additional 23.4% of PAI-1 variation in the patients.
Analysis based on these adjusted PAI-1 values showed an association with Hindlll genotype (Table 3) within both patient and control samples, with the HI genotype associated with higher levels of plasma PAI-1 than the 212 genotype. In the patient sample, mean PAI-1 levels for the 111 group were 29% higher than the 212 group (p=0.068 in a / test).
One-way ANOVA on the (C-A) n repeat data (Figure 3) showed a significant association between (C-A) n repeat genotype and PAI-1 levels in the patients (/?=0.03), with the shorter alleles associated with higher levels. A similar trend was observed in the control sample, although not at a significant level (p=0.14). Due to the large numbers of alleles present in the sample, we have chosen to use the average excess calculation to estimate the effect on PAI-1 levels associated with this polymorphism. 30 
"
31 Average excess is an estimate of the average effect each allele has on PAI-1 levels within the sample. Results of the calculation of average excess for each (C-A) n repeat allele are shown in Table 4 . In both patients and controls, the z+2 allele and all smaller alleles (6) PAI-1, plasminogen activator inhibitor-1. Calculations were performed as described by Templeton.
31
(i.e., z, z-2) are associated with a higher plasma PAI-1, and those alleles of a greater size than z+4 are generally associated with a lower plasma PAI-1. Next, we investigated whether the effect on plasma PAI-1 levels of increasing plasma triglycerides, incremental insulin during OGTT, and BMI was the same in individuals with different genotypes. Regression analysis was performed separately in each HindlU genotype class, and the regression slope for each variable was compared (Table 5 ). These results show a different slope in each genotype class for VLDLTGs. PAI-1 levels for the 1/1 genotype class increase at a greater rate with increasing VLDL than the 1/2 and 2/2 classes in both patient and control samples. The data also show that insulin response to oral glucose challenge has a significant effect only on individuals of the HindlH 2/2 genotype in both patient and control samples (p<0.01). Analysis of this type was not possible on the (C-A) n repeat polymorphism due to the small number of individuals in each of the 17 genotype classes.
Discussion
The use of nonfunctional sequence variations (e.g., RFLPs) as markers for other functionally important changes in the same gene relies on these two differences being in linkage disequilibrium, 32 where the presence of one allele is indicative of the presence of the other at a frequency higher than that expected by chance alone. This principle has been used widely in population studies with RFLPs to identify candidate genes that are important in the development of polygenic disease. 33 - 34 One way to do this is to compare the frequency of polymorphic alleles in control and patient populations. This requires the use of very large samples to detect significant differences in frequency because it relies on an association between a genetic marker and disease incidence. This is particularly difficult with a multifactorial disease, where there are many genetic and other factors involved in any one individual's presentation as a patient. Studies on the association between polymorphisms in a candidate gene and the plasma level of its gene product do not require such large numbers to detect an association, and they suggest a functional variation in sequence in the same gene. This technique has been used in the past to identify potential functional changes in gene sequence at the fibrinogen 35 41 and raises the possibility that VLDL and insulin might be major physiologic regulators of PAI-1 activity in plasma. Recent experiments on hepatoma cells in vitro also suggest a regulatory role for insulin. 43 Our data suggest that this regulation of PAI-1 by VLDL and insulin is genotype specific: Patients and controls of //indlll genotype 1/1 show a twofold to threefold greater increase in plasma PAI-1 with an increase in VLDL-TGs than do individuals of genotype 2/2 (Table 5) , whereas the OGTT data only have a significant effect on 2/2 individuals. It is possible that the Hindlll RFLP is in linkage disequilibrium with a base change at a site of functional importance in the regulation of PAI-1 by VLDL/ insulin. One such site would be a sequence in the PAI-1 gene involved in the binding of a transcription factor whose level is indirectly or directly altered by VLDL levels or VLDL composition.
The data show an association between Hindlll genotype and plasma PAI-1 levels although this was not significant at conventional levels. The Hindlll 1 allele in both patient and control samples was associated with higher levels ( In both the control and patient samples analyzed here, a clear association between the smaller (C-A) n repeat genotype and raised plasma PAI-1 levels was found. This association is most evident within the sample of young male MI survivors, but the same trend is also apparent within the control sample. There is recent evidence that purine-pyrimidine repeats of this kind may be sites for topoisomerase II activity, which could well be important in transcription. 42 Such a direct effect is unlikely in this case because the polymorphism is in intron 3 of the gene, but it is instead more likely to be acting as a marker for a functional change elsewhere in the PAI-1 gene.
The dinucleotide repeat polymorphism appears to be in linkage disequilibrium with the Hindlll RFLP (Table 2 ). This association of the shorter alleles with the Hindlll 1 allele and with higher PAI-1 levels suggests that the dinucleotide repeat polymorphism arises through a slippage mechanism rather than any recombination event and that the longer the stretch of dinucleotide repeats, the more likely this slippage event is to occur. This hypothesis is supported by the fact that there were only two alleles smaller than the predominant z allele in the samples genotyped and five that were larger. The distribution of allele frequency in the two samples was found to be bimodal, with the antinode around the z+6 allele ( Figure 3 , upper panel). Other studies with dinucleotide repeat polymorphisms have also found bimodal distributions of allele frequency, but the significance of this is unknown. 44 We have demonstrated that genetic variation in the PAI-1 gene is a significant factor in determining levels of PAI-1 in plasma in two independent samples. It is most likely that the (C-A) n repeat polymorphism and Hindlll RFLP are in linkage disequilibrium with a sequence variation elsewhere in the gene that influences the expression of the PAI-1 gene. Regulation of the gene by several different factors in vitro has previously been shown to be important in controlling synthesis of PAI-1.
15 -17 These experiments indicate that regulation of PAI-1 at the transcriptional level is a significant component in determining the amount of active PAI-1 in plasma. Since PAI-1 is an important component of the fibrinolytic system, identification of a sequence variation in the PAI-1 gene that affects its expression would be useful to identify an individual predisposed to arterial and thrombotic disease.
